A Multiple Ascending Dose Study of MEDI7247 in Participants with Selected Relapsed/Refractory Hematological Malignancies

Study identifier:D8540C00001

ClinicalTrials.gov identifier:NCT03106428

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancies

Medical condition

Acute Myeloid Leukemia

Phase

Phase 1

Healthy volunteers

No

Study drug

MEDI7247

Sex

All

Actual Enrollment

67

Study type

Interventional

Age

18 Years - 100 Years

Date

Study Start Date: 29 Mar 2017
Primary Completion Date: 03 Jan 2020
Study Completion Date: 03 Jan 2020

Study design

Allocation: Non-randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2020 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria